Medications for depression are usually prescribed based on symptoms and medical history. For some people, the first antidepressant tried relieves depression symptoms and has tolerable side effects. For many others, however, finding the right medication takes trial and error. For some people, it can take several months or longer to find the right antidepressant.
Genotyping tests, such as cytochrome P450 tests, may speed up the identification of medications that are more likely to be better processed by your body. Ideally, better processing would lead to fewer side effects and improved effectiveness. CYP450 tests are generally used only when initial antidepressant treatments aren't successful.
Genotyping tests are also used in other areas of medicine. For example, the CYP2D6 test can help determine whether certain cancer medications, such as tamoxifen for breast cancer, are likely to be more effective. The CYP2C9 test can help determine appropriate dosing of the blood thinner warfarin to reduce the risks of adverse effects.
Aug. 21, 2015
- Hall-Flavin DK, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenetics and Genomics. 2013;23:535.
- Altar CA, et al. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. The Pharmacogenomics Journal. In press. Accessed July 13, 2015.
- Biernacka JM, et al. The International SSRI Pharmacogenomics Consortium (ISPC): A genome-wide association study of antidepressant treatment response. Translational Psychiatry. 2015;5:e533.
- Genetic testing — CYP450 genotyping to predict response to SSRIs used to treat non-psychotic depression in adults: EGAPP recommendation. Centers for Disease Control and Prevention. http://www.cdc.gov/genomics/gtesting/EGAPP/recommend/CYP450.htm. Accessed July 13, 2015.
- Genetic testing — General public: CYP450 genotyping and use of SSRI drugs for depression in adults. Centers for Disease Control and Prevention. http://www.cdc.gov/genomics/gtesting/EGAPP/recommend/CYP450_consumer.htm. Accessed July 13, 2015.
- Perlis RH. Pharmacogenomic testing and personalized treatment of depression. Clinical Chemistry. 2014;60:53.
- AskMayoExpert. Antidepressant medications and pharmacogenomics. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
- Samer CF, et al. Applications of CYP450 testing in the clinical setting. Molecular Diagnosis and Therapy. 2013;17:165.
- Tantisira K, et al. Overview of pharmacogenomics. http://www.uptodate.com/home. Accessed July 13, 2015.
- Steimer W. Pharmacogenetics and psychoactive drug therapy: Ready for the patient? Therapeutic Drug Monitoring. 2010;32:381.
- Mrazek DA, et al. Facilitating clinical implementation of pharmacogenomics. JAMA. 2011;306:304.
- Veldic M (expert opinion). Mayo Clinic, Rochester, Minn. Aug. 14, 2014.
- Kung S (expert opinion). Mayo Clinic, Rochester, Minn. July 23, 2015.